• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Enliven Therapeutics, Inc. - Common Stock (NQ:ELVN)

    25.87 +0.09 (+0.35%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 703,059
    Open 25.62
    Bid (Size) 25.85 (200)
    Ask (Size) 25.88 (500)
    Prev. Close 25.78
    Today's Range 25.44 - 26.21
    52wk Range 13.30 - 29.98
    Shares Outstanding 41,151,111
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
    Issued on behalf of Oncolytics Biotech Inc. 
    From Equity Insider
    Via GlobeNewswire
    S&P 500, Nasdaq Futures Waver Ahead Of Supreme Court Ruling On Trump Tariffs: Why OPEN, ACON, FLYX, OSCR Are Trending After-Hours ↗
    Via Stocktwits
    Topics Government Stocks

    Performance

    YTD
    +66.5%
    +66.5%
    1 Month
    +58.7%
    +58.7%
    3 Month
    +20.9%
    +20.9%
    6 Month
    +25.2%
    +25.2%
    1 Year
    +21.5%
    +21.5%

    More News

    Read More
    Here are the top movers in Thursday's session. ↗
    Via Chartmill
    News headline image
    ELVN Stock Shot Up 60% Today – What’s Driving The Rally? ↗
    Via Stocktwits
    These stocks are gapping in today's session ↗
    Via Chartmill
    News headline image
    Resemble AI Unleashes Chatterbox Turbo: A New Era for Open-Source Real-Time Voice AI
    Via TokenRing AI
    Topics Artificial Intelligence Fraud Hacking
    News headline image
    With a 150% Rally and Big 2026 Catalysts Ahead, Is Amylyx Stock Getting a Second Chance? ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Relay Therapeutics Stock Has Jumped 60% in a Year — And One Investor Just Bought Nearly 4 Million More Shares ↗
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    12 Health Care Stocks Moving In Monday's Intraday Session ↗
    Via Benzinga
    News headline image
    What's going on in today's pre-market session ↗
    Via Chartmill
    News headline image
    Enliven Posts Loss Beat and Cash Surge ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Meta To Rally Around 3%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
    Via Benzinga
    News headline image
    Enliven Short Interest Falls To 14-Month Low After Leukemia Trial Data, Goldman Initiates With ‘Buy’ ↗
    Via Stocktwits
    News headline image
    12 Health Care Stocks Moving In Friday's Intraday Session ↗
    Via Benzinga
    News headline image
    Greenbrier, RPM International, CVRx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
    Via Benzinga
    News headline image
    Active Biotech Alert: FDA Approves 16 New Cancer Treatments as Global Cancer Rates Skyrocket
    Via FinancialNewsMedia
    Topics Artificial Intelligence
    News headline image
    Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst ↗
    Via Benzinga
    News headline image
    ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q2 2024 ↗
    Via InvestorPlace
    News headline image
    ELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024 ↗
    Via InvestorPlace
    News headline image
    Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program ↗
    Via Benzinga
    News headline image
    Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
    Via Benzinga
    News headline image
    Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday ↗
    Via Benzinga
    Topics Stocks

    Frequently Asked Questions

    Is Enliven Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Enliven Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Enliven Therapeutics, Inc. - Common Stock trade on?
    Enliven Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Enliven Therapeutics, Inc. - Common Stock?
    The ticker symbol for Enliven Therapeutics, Inc. - Common Stock is ELVN on the Nasdaq Stock Market
    What is the current price of Enliven Therapeutics, Inc. - Common Stock?
    The current price of Enliven Therapeutics, Inc. - Common Stock is 25.87
    When was Enliven Therapeutics, Inc. - Common Stock last traded?
    The last trade of Enliven Therapeutics, Inc. - Common Stock was at 01/26/26 04:00 PM ET
    What is the market capitalization of Enliven Therapeutics, Inc. - Common Stock?
    The market capitalization of Enliven Therapeutics, Inc. - Common Stock is 1.06B
    How many shares of Enliven Therapeutics, Inc. - Common Stock are outstanding?
    Enliven Therapeutics, Inc. - Common Stock has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.